Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel T Wilkinson

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
The Yale Journal of Biology and Medicine|March 7, 2014
Reflections on residency: pre-roundingSamuel T Wilkinson
Missouri Medicine|February 26, 2014
Medical and recreational marijuana: commentary and review of the literatureSamuel T Wilkinson
The Journal of Clinical Psychiatry|September 16, 2022
Ketamine in the Real World: Where Do We Go From Here?Samuel T Wilkinson
Depression and Anxiety|April 16, 2016
KETAMINE: A POTENTIAL RAPID-ACTING ANTISUICIDAL AGENT?Samuel T Wilkinson, Gerard Sanacora
The Journal of ECT|June 15, 2018
Access to Outpatient Electroconvulsive Therapy at VA Medical Centers - ReplySamuel T Wilkinson, Robert Rosenheck
JAMA|August 15, 2017
Considerations on the Off-label Use of Ketamine as a Treatment for Mood DisordersSamuel T Wilkinson, Gerard Sanacora
JAMA Psychiatry|April 16, 2025
Issues in Clinical Trial Design-Lessons From the FDA's Rejection of MDMASamuel T Wilkinson, Gerard Sanacora
Journal of Affective Disorders|September 6, 2022
At-home ketamine; still a lot to learnSamuel T Wilkinson, Gerard Sanacora
The Psychiatric Clinics of North America|May 6, 2023
The Role of Psychotherapy in the Management of Treatment-Resistant DepressionTaylor Rogan, Samuel T Wilkinson
Drug Discovery Today|November 18, 2018
A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systemsSamuel T Wilkinson, Gerard Sanacora
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
The Yale Journal of Biology and Medicine|March 7, 2014
Reflections on residency: pre-roundingSamuel T Wilkinson
Missouri Medicine|February 26, 2014
Medical and recreational marijuana: commentary and review of the literatureSamuel T Wilkinson
The Journal of Clinical Psychiatry|September 16, 2022
Ketamine in the Real World: Where Do We Go From Here?Samuel T Wilkinson
Depression and Anxiety|April 16, 2016
KETAMINE: A POTENTIAL RAPID-ACTING ANTISUICIDAL AGENT?Samuel T Wilkinson, Gerard Sanacora
The Journal of ECT|June 15, 2018
Access to Outpatient Electroconvulsive Therapy at VA Medical Centers - ReplySamuel T Wilkinson, Robert Rosenheck
JAMA|August 15, 2017
Considerations on the Off-label Use of Ketamine as a Treatment for Mood DisordersSamuel T Wilkinson, Gerard Sanacora
JAMA Psychiatry|April 16, 2025
Issues in Clinical Trial Design-Lessons From the FDA's Rejection of MDMASamuel T Wilkinson, Gerard Sanacora
Journal of Affective Disorders|September 6, 2022
At-home ketamine; still a lot to learnSamuel T Wilkinson, Gerard Sanacora
The Psychiatric Clinics of North America|May 6, 2023
The Role of Psychotherapy in the Management of Treatment-Resistant DepressionTaylor Rogan, Samuel T Wilkinson
Drug Discovery Today|November 18, 2018
A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systemsSamuel T Wilkinson, Gerard Sanacora
Pageof 11